Document is current

Article History

Received: 18 November 2024

Accepted: 21 July 2025

First Online: 16 August 2025

Competing interests

: The authors declare the following competing interests: L. Pontolillo reports travel grants from Pifzer and Eli Lilly, all outside the submitted work. A.A. Davis reports grants funding from Breast Cancer Alliance; participating on a Data Safety Monitoring Board or Advisory Board from Pfizer and Biotheranostics; personal fee from Onclive and travel support from DAVA Oncology, all outside the submitted work. L. Gerratana reports consulting fees or payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AstraZeneca, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Incyte, Novartis, Pfizer, Merck Sharp & Dohme, Menarini Stemline and Abbvie; travel support form Menarini Stemline; participating on a Data Safety Monitoring Board or Advisory Board from Incyte, Eli Lilly, Menarini Stemline, all outside the submitted work. A.J.Medford reports consulting fees from AstraZeneca, Guardant Health, Illumina, Myriad Genetics, Science for America and payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Natera, all outside the submitted work. K. Clifton reports participating on Advisory Board from Novartis, outside the submitted work. M. Lipsyc-Sharf reports payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Exact Sciences and participating on a Data Safety Monitoring Board or Advisory Board from Natera, all outside the submitted work. E.Bria reports institutional grants funding from AstraZeneca and Roche; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from MSD, AstraZeneca, Roche, Pfizer, Novartis and Takeda; travel support from AstraZeneca, MSD and Roche; participation on a Data Safety Monitoring Board or Advisory Board from MSD, Eli-Lilly, AstraZeneca, Janseen, BMS, Celltrion, all outside the submitted work. C.X. Ma reports research grants from Pfizer, Puma, AstraZeneca, Genentech; consulting fees and participating on advisory board from Puma, Pfizer, Novartis, AstraZeneca, all outside the submitted work. A. Bardia reports grant fundings and consulting fees from Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, AstraZeneca/Daiichi Sankyo, Eli Lilly, travel grants from AstraZeneca, Daiichi Sankyo and Gilead, all outside the submitted work. C. Reduzzi reports grants funding from American Association for Cancer Research, outside the submitted work. M. Cristofanilli reports payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Pfizer, participating on a Data Safety Monitoring Board or Advisory Board from Merck and AstraZeneca, leadership role as President for Inflammatory Breast Cancer International Consortium, all outside the submitted work. J. Wang, E. Nicolò, M. Velimirovic; S. Warrior, E. Podany, M.S. Serafini, L. Munoz Arcos, E. Molteni, C. Gianni, C. Dai, D. Giannarelli declare no conflict of interest.